87 related articles for article (PubMed ID: 3555058)
1. In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.
Kayser FH; Novak J
Am J Med; 1987 Apr; 82(4A):33-9. PubMed ID: 3555058
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of ciprofloxacin against gram-positive cocci.
Barry AL; Jones RN
Am J Med; 1987 Apr; 82(4A):27-32. PubMed ID: 3578323
[TBL] [Abstract][Full Text] [Related]
3. Overview of preclinical studies with ciprofloxacin.
Sanders CC; Sanders WE; Goering RV
Am J Med; 1987 Apr; 82(4A):2-11. PubMed ID: 3646829
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E
Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
[TBL] [Abstract][Full Text] [Related]
6. Overview of Scandinavian in vitro studies with ciprofloxacin.
Forsgren A
Scand J Infect Dis Suppl; 1989; 60():16-22. PubMed ID: 2667106
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics.
Debbia E; Schito GC; Nicoletti G; Speciale A
Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779
[TBL] [Abstract][Full Text] [Related]
8. [Susceptibility of bacteria isolated from clinical material to ciprofloxacin].
Namysł E; Galiński J; Szponar M; Piechowicz L
Med Dosw Mikrobiol; 1995; 47(1-2):5-9. PubMed ID: 8523970
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.
Kowalski RP; Karenchak LM; Gordon YJ
Cornea; 1998 May; 17(3):282-7. PubMed ID: 9603384
[TBL] [Abstract][Full Text] [Related]
10. The comparative activity of twelve 4-quinolone antimicrobials against gram-positive and gram-negative anaerobes.
Robbins MJ; O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
Drugs Exp Clin Res; 1985; 11(7):431-4. PubMed ID: 3836865
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
Streit JM; Jones RN; Sader HS
J Antimicrob Chemother; 2004 Apr; 53(4):669-74. PubMed ID: 14985278
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria.
van der Auwera P; Vandermies A; Grenier P; Klastersky J
Drugs Exp Clin Res; 1987; 13(3):125-32. PubMed ID: 3622241
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
14. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
15. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
16. [Comparative in vitro bacteriostatic and bactericidal effect of 5 macrolides: roxithromycin, erythromycin, oleandomycin, josamycin and spiramycin against 284 hospital bacterial strains].
Le Noc P; Croize J; Bryskier A; Le Noc D; Robert J
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):553-9. PubMed ID: 2797879
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of fosfomycin against 'problem' gram-positive cocci.
Hamilton-Miller JM
Microbios; 1992; 71(287):95-103. PubMed ID: 1453987
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of levofloxacin against gram-positive bacteria.
Montanari MP; Mingoia M; Marchetti F; Varaldo PE
Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains.
Jones RN
J Chemother; 2001 Aug; 13(4):363-76. PubMed ID: 11589478
[TBL] [Abstract][Full Text] [Related]
20. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.
Mendes RE; Sader HS; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1579-81. PubMed ID: 24505091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
